Cadent Therapeutics

Cadent Therapeutics is a biopharmaceutical company focused on developing first-in-class allosteric modulators to address unmet needs in central nervous system (CNS) disorders, including cognitive and movement disorders. The company leverages its extensive industry experience in medicinal chemistry, target selection, drug discovery, and drug optimization to advance a pipeline of novel allosteric modulators of ion channels. These ion channels, such as SK channels and NMDA receptors, are crucial for modulating neuronal communication and integration within the CNS. Cadent Therapeutics aims to positively modulate NMDA receptors to reverse hypofunction in schizophrenia patients and restore cognitive balance. Additionally, the company is developing positive allosteric modulators (PAMs) of SK channels to treat essential tremor (ET) and spinocerebellar ataxia (SCA). By targeting specific patient subsets based on genetics or other factors, Cadent Therapeutics strives to identify patients who will benefit most from their treatments, ensuring optimal efficacy with minimal side effects. The company operates in the biopharmaceutical market, serving patients with CNS disorders and generating revenue through the development and commercialization of its therapeutic candidates.

Keywords: allosteric modulators, CNS disorders, NMDA receptors, SK channels, schizophrenia, essential tremor, spinocerebellar ataxia, drug discovery, neuronal communication, biopharmaceutical.